BioNexus Gene Lab Corp. (BGLC) vs Globavend Holdings Limited (GVH)

A side-by-side comparison of BioNexus Gene Lab Corp. and Globavend Holdings Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — BGLC vs GVH

growth of $100 · dividends reinvested · last 3y
BGLC -67.0% (-30.9%/yr)GVH -99.8% (-87.1%/yr)BGLC compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $100202420252026$33$0
BGLC GVH

BGLC vs GVH: by the numbers

  • •BGLC is the larger company ($3M vs $3M market cap).
  • •GVH is profitable (0.80% net margin) while BGLC runs a net loss (-82.36%).

Metrics side by side

Valuation

MetricBGLCGVH
P/E ratioN/A7.07
P/S ratio0.950.09
P/B ratio0.380.38
FCF yieldN/A4.55%

Profitability

MetricBGLCGVH
Gross margin11.64%7.74%
Operating margin-42.54%-0.84%
Net margin-82.36%0.80%
ROE-33.11%3.24%
ROIC-32.71%-2.06%

Growth (annualized)

MetricBGLCGVH
Revenue CAGR (5Y)-31.68%N/A
Total return CAGR (5Y)-61.00%N/A

Frequently asked

Is BGLC or GVH more profitable?
GVH runs the higher net margin — BGLC at -82.36% versus GVH at 0.80%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.